Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.
|Original language||English (US)|
|Number of pages||4|
|Journal||Cell Stem Cell|
|State||Published - Aug 4 2016|
Bibliographical notePublisher Copyright:
© 2016 Elsevier Inc.